Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation in treating patients who have multiple myeloma or other B-cell cancers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical College of Wisconsin
• Treatments: Cyclophosphamide; Melphalan; Sargramostim

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed multiple myeloma or other B-cell malignancy including non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, or amyloidosis

• Non-Hodgkin's lymphoma with T-cell immunophenotypes included

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• Karnofsky 60-100%

Life expectancy:

• Not specified

Hematopoietic:

• WBC at least 2,000/mm^3 (unless due to disease)

• Platelet count at least 100,000/mm^3 (unless due to disease)

Hepatic:

• Not specified

Renal:

• Not specified

Cardiovascular:

• LVEF at least 40%

Pulmonary:

• DLCO or FVC and FEV1 at least 50% of predicted unless due to restriction from volume loss secondary to disease

Other:

• HIV negative

• No overt infection or unexplained fever requiring broad spectrum antibiotics

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• At least 2 weeks since prior biologic therapy

Chemotherapy:

• At least 2 weeks since other prior chemotherapy and recovered

Endocrine therapy:

• At least 2 weeks since prior endocrine therapy

• Concurrent steroids allowed

Radiotherapy:

• Not specified

Surgery:

• Not specified